Overview
Primary neuroendocrine carcinoma of the stomach is a rare malignancy. Gastric cancer, predominantly adenocarcinoma, is the third leading cause of cancer-related deaths globally and often presents at an advanced stage, impacting prognosis 1.Diagnosis
Histologic type classification is standard for gastric cancers 1.
Biomarker testing, including HER2 status, microsatellite instability (MSI), and PD-L1 expression, is impactful in clinical practice 1.Management
Systemic therapy can offer palliation, improved survival, and enhanced quality of life for patients with locally advanced or metastatic disease 1.
Targeted therapies such as trastuzumab, nivolumab, and pembrolizumab have shown encouraging results in clinical trials for advanced or metastatic disease 1.
Palliative management, including systemic therapy, chemoradiation, and/or best supportive care, is recommended for unresectable or metastatic cancer 1.
Multidisciplinary team management is essential for localized gastric cancer 1.Key Recommendations
Biomarker testing, specifically HER2, MSI, and PD-L1 status, significantly impacts clinical practice and patient care for gastric cancer 1. (Evidence: Moderate)
Systemic therapy is recommended for palliation, survival improvement, and enhanced quality of life in patients with locally advanced or metastatic gastric cancer 1. (Evidence: Moderate)
Palliative management, potentially including systemic therapy, chemoradiation, and/or best supportive care, is advised for all patients with unresectable or metastatic gastric cancer 1. (Evidence: Moderate)References
1 Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C et al.. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2022. link